Smith & Nephew SNATS, Inc. (NYSE:SNN) Receives Consensus Recommendation of "Hold" from Brokerages

Key Points

• Smith & Nephew SNATS, Inc. (NYSE:SNN) currently holds an average analyst rating of "Hold" from six brokerages, reflecting a consensus view among analysts.
• Canaccord Genuity recently increased its price target for the stock from $28.00 to $36.00, while HSBC downgraded its rating from "buy" to "hold."
• The company announced a semi-annual dividend of $0.285, with a dividend payout ratio of 41.20%, scheduled for payment on November 7th.

Shares of Smith & Nephew SNATS, Inc. (NYSE:SNN - Get Free Report) have earned a consensus recommendation of "Hold" from the six research firms that are covering the stock, MarketBeat.com reports. Six research analysts have rated the stock with a hold recommendation. The average 1-year price target among brokerages that have covered the stock in the last year is $36.00.

Several equities analysts have commented on SNN shares. HSBC lowered shares of Smith & Nephew SNATS from a "buy" rating to a "hold" rating in a research report on Friday, April 25th. Hsbc Global Res lowered shares of Smith & Nephew SNATS from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 25th. Wall Street Zen lowered shares of Smith & Nephew SNATS from a "strong-buy" rating to a "buy" rating in a research report on Friday. Finally, Canaccord Genuity Group increased their price objective on shares of Smith & Nephew SNATS from $28.00 to $36.00 and gave the company a "hold" rating in a research report on Monday, August 18th.

Institutional Investors Weigh In On Smith & Nephew SNATS

Hedge funds and other institutional investors have recently made changes to their positions in the company. Hexagon Capital Partners LLC raised its stake in shares of Smith & Nephew SNATS by 63.3% in the first quarter. Hexagon Capital Partners LLC now owns 1,047 shares of the medical equipment provider's stock valued at $30,000 after acquiring an additional 406 shares during the period. Richards Merrill & Peterson Inc. raised its stake in shares of Smith & Nephew SNATS by 500.0% in the first quarter. Richards Merrill & Peterson Inc. now owns 1,200 shares of the medical equipment provider's stock valued at $34,000 after acquiring an additional 1,000 shares during the period. AlphaCore Capital LLC purchased a new stake in shares of Smith & Nephew SNATS in the second quarter valued at $44,000. Bessemer Group Inc. raised its stake in shares of Smith & Nephew SNATS by 3,471.4% in the first quarter. Bessemer Group Inc. now owns 1,750 shares of the medical equipment provider's stock valued at $49,000 after acquiring an additional 1,701 shares during the period. Finally, Banque Transatlantique SA purchased a new stake in shares of Smith & Nephew SNATS in the first quarter valued at $52,000. Hedge funds and other institutional investors own 25.64% of the company's stock.

Smith & Nephew SNATS Price Performance

SNN stock traded up $0.5630 during trading on Monday, hitting $37.5330. 603,940 shares of the company's stock traded hands, compared to its average volume of 984,738. Smith & Nephew SNATS has a 52 week low of $23.69 and a 52 week high of $37.58. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.40 and a current ratio of 3.00. The business has a fifty day simple moving average of $31.96 and a 200 day simple moving average of $29.22. The stock has a market capitalization of $16.44 billion, a price-to-earnings ratio of 17.38, a P/E/G ratio of 1.02 and a beta of 0.68.

Smith & Nephew SNATS Cuts Dividend

The company also recently announced a semi-annual dividend, which will be paid on Friday, November 7th. Stockholders of record on Friday, October 3rd will be paid a $0.285 dividend. The ex-dividend date of this dividend is Friday, October 3rd. This represents a dividend yield of 210.0%. Smith & Nephew SNATS's dividend payout ratio is currently 26.39%.

About Smith & Nephew SNATS

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.